Equities

EBAC

KYG3167F1028

Market Closed - Nasdaq Other stock markets 16:30:00 2024-06-25 EDT			5-day change	1st Jan Change
11.82 ^USD	-0.30%		+0.64%	+5.67%

2023	European Biotech Acquisition Corp.(NasdaqCM:EBAC) dropped from NASDAQ Composite Index	CI
2023	Oculis SA completed the acquition of European Biotech Acquisition Corp. from Lsp Sponsor Ebac B.V. and others in a reverse merger.	CI

European Biotech Acquisition Corp. announced that it has received $4.55096 million in funding from Lsp Sponsor Ebac B.V.

May 02, 2021

On May 3, 2021, European Biotech Acquisition Corp. (NasdaqCM:EBAC.U) closed the transaction. The company amended the terms of the transaction and issued 15,096 units for proceeds of $150,960 in its second tranche closing, bringing the total gross proceeds raised in the transaction to $4,550,960.

Latest news about EURO BIOT

European Biotech Acquisition Corp.(NasdaqCM:EBAC) dropped from NASDAQ Composite Index	23-03-02	CI
Oculis SA completed the acquition of European Biotech Acquisition Corp. from Lsp Sponsor Ebac B.V. and others in a reverse merger.	23-03-01	CI
European Biotech Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
European Biotech Acquisition Corp. Auditor Raises 'Going Concern' Doubt	23-02-27	CI
European Biotech Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
European Biotech Acquisition, Oculis Strike Merger Agreement	22-10-17	MT
Oculis SA entered into a Business Combination Agreement to acquire European Biotech Acquisition Corp. from Lsp Sponsor Ebac B.V. in a reverse merger for approximately $210 million.	22-10-16	CI
European Biotech Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
European Biotech Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
European Biotech Acquisition Corp. Auditor Raises 'Going Concern' Doubt	22-03-30	CI
Certain Class B Ordinary Shares of European Biotech Acquisition Corp. are subject to a Lock-Up Agreement Ending on 15-SEP-2021.	21-09-14	CI
European Biotech Acquisition Corp.(NasdaqCM:EBAC) added to NASDAQ Composite Index	21-05-19	CI
European Biotech Acquisition Corp. announced that it has received $4.55096 million in funding from Lsp Sponsor Ebac B.V.	21-05-02	CI
European Biotech Acquisition Corp. Appoints Mohammad Sohail Fazeli to the Board	21-03-18	CI
European Biotech Acquisition Corp. has completed an IPO in the amount of $120 million.	21-03-18	CI
European Biotech Acquisition Corp. has filed an IPO in the amount of $100 million.	21-02-17	CI
European Biotech Acquisition Corp. announced that it expects to receive $4 million in funding from Lsp Sponsor Ebac B.V.	21-02-16	CI

Chart EURO BIOT

Duration

Period

More charts

Company Profile

European Biotech Acquisition Corp is a blanc check company based in the Netherlands. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The Company intends to primarily seek to identify a company within the European life sciences industry. The aim of the Company is investments in therapeutic drug candidates in clinical development across a range of therapeutic areas, including oncology, diabetes, cardiology, central nervous system (CNS) and orphan diseases.

Sector

More about the company

Income Statement Evolution

More financial data